The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade.
about
Diagnosis and differential diagnosis of hepatic graft versus host disease (GVHD)Defibrotide in the treatment of hepatic veno-occlusive diseaseSinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT)Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research.Defibrotide: a review of its use in severe hepatic veno-occlusive disease following haematopoietic stem cell transplantation.Sinusoidal obstruction syndrome (hepatic veno-occlusive disease)Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplantBiomarkers for Diagnosis and Prognosis of Sinusoidal Obstruction Syndrome after Hematopoietic Cell TransplantationPretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcomeEscalation to High-Dose Defibrotide in Patients with Hepatic Veno-Occlusive Disease.Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies.Veno-occlusive disease of the liver in the absence of elevation in bilirubin in pediatric patients after hematopoietic stem cell transplantation.Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failureSafety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease.Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation.Pharmacokinetic profile of defibrotide in patients with renal impairment.Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapySevere Hepatic Sinusoidal Obstruction Syndrome in a Child Receiving Vincristine, Actinomycin-D, and Cyclophosphamide for Rhabdomyosarcoma: Successful Treatment with DefibrotideGemtuzumab ozogamicin in acute myeloid leukemia revisited.Complications of allogeneic hematopoietic stem cell transplantation.How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation.Prophylaxis and treatment recommendations for sinusoidal obstruction syndrome in adult and pediatric patients undergoing hematopoietic stem cell transplant: a review of the literature.Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.Burden of illness associated with sinusoidal obstruction syndrome/veno-occlusive disease in patients with hematopoietic stem cell transplantation.Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejeThe budget impact and cost-effectiveness of defibrotide for treatment of veno-occlusive disease with multi-organ dysfunction in patients post-hematopoietic stem cell transplant.Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT.Hepatobiliary quiz (answers)-13 (2015).Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes.Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.Veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic stem cell transplantation: Middle East/North Africa regional consensus on prevention, diagnosis and management.Evaluation of thromboelastometry parameters as predictive markers for sinusoidal obstruction syndrome in patients undergoing allogeneic stem cell transplantation for acute leukaemia.Human herpesvirus 6 reactivation on the 30th day after allogeneic hematopoietic stem cell transplantation can predict grade 2-4 acute graft-versus-host disease.Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome.Tolvaptan as an alternative treatment for refractory fluid retention associated with sinusoidal obstruction syndrome after allogeneic stem cell transplantation.Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT.Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation.Infusion of endothelial progenitor cells ameliorates liver injury in mice after haematopoietic stem cell transplantation.
P2860
Q26749007-244A6B08-E574-4B39-AABC-764D9914C95BQ28068332-F581BFFB-E7DC-4918-822E-E277294AD231Q28083417-F1BAEDEE-8578-4015-9B54-611EAF0B8521Q31083746-80197AE3-C9B1-4EB7-99B1-6A9618CCC3C9Q34445293-F2386F17-5796-4FAE-B2DC-51576E2215A0Q34983459-445128C5-E14A-41CF-9843-BE7DE2D11592Q35787013-99108654-219E-41AE-8C90-C9023D0F2F21Q36055238-EBDCB2C3-DDE3-43EC-A82A-AC4F60E4245DQ36059184-2D60DA16-6C65-4F96-B8C9-83366F897D5FQ36264751-A165E9A9-0CA5-47E2-A299-7AB5A7D69BFFQ36445665-BF091103-84B5-47F9-AFA2-2F43AFDFB7BBQ36751874-968EB046-19E1-436B-A9E1-E74BC0065101Q36755484-EBFF84E0-0F78-4EFB-8B23-A0659A5A4BABQ36768621-E3547B9A-0D08-43E2-BB4E-4883C8662C23Q37073000-85EC1631-6B43-4115-8B02-C79BDCD6B9A0Q37194132-75E29FF6-0959-4431-90A4-A018396D4663Q37216454-CA4862EA-3AC8-4A89-BBC7-323CB9A8996EQ37367452-46BADDA5-CE8D-425B-A49B-0ECACB8EA62EQ38215269-4DF77CC9-EFA7-4B8C-8CA6-23F876CFBCD0Q38217938-400FE34B-B2DD-4BC2-BA45-B6356C5BC0F3Q38268712-EABD8FC8-B5A1-4F22-90CA-71E417E5C3CBQ38540846-3C6F7AE4-422D-4C05-85D9-139988328934Q38616218-5CF78AC6-B891-4CBA-9673-FA1708891A19Q38754283-FC6EFCB8-9959-4B52-A7E7-7DDCDED0E477Q38818973-442A357A-375E-4EDD-B3B8-737B81BDC633Q38977681-82F5DC13-3694-423A-8BE7-813C179DF506Q39069407-0EB7CEEE-3ADE-4E93-ABC1-A01811B5C8BFQ39374803-B4D55E29-3724-403A-B6CB-19F649DE70D8Q40112074-E4D9AF4D-1D94-48CE-A289-3C837CABC326Q40280061-7A99A257-CC90-4340-8140-0E52F71D2256Q40288619-7082FE20-E6CF-4677-9561-F6CF1DD28695Q40386808-4196114C-5738-47C8-992B-4BD6672C5874Q40433391-ABC94827-7E7D-4238-9676-593651E39D9FQ41709123-6D33CBB5-27E2-4159-BC90-40DEB944D8B5Q42219821-2215EA06-9206-436F-970C-86CF9D783EBFQ43429437-0CA0EE30-02C8-4B98-9C73-7876B07EF2BEQ43988768-69E1B71C-2D9E-432B-B55E-CD6C33DA42BBQ48349415-BEAC3AE4-D6F2-46C9-87C5-ABEFEBC56F3DQ49276207-54A6181B-BE80-4F7A-926A-E4AE220D0C64Q50989392-A43F156C-54C4-4F1C-9CC9-F15E6554CAE6
P2860
The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The incidence of veno-occlusiv ...... improved over the last decade.
@ast
The incidence of veno-occlusiv ...... improved over the last decade.
@en
The incidence of veno-occlusiv ...... improved over the last decade.
@nl
type
label
The incidence of veno-occlusiv ...... improved over the last decade.
@ast
The incidence of veno-occlusiv ...... improved over the last decade.
@en
The incidence of veno-occlusiv ...... improved over the last decade.
@nl
prefLabel
The incidence of veno-occlusiv ...... improved over the last decade.
@ast
The incidence of veno-occlusiv ...... improved over the last decade.
@en
The incidence of veno-occlusiv ...... improved over the last decade.
@nl
P2093
P1476
The incidence of veno-occlusiv ...... improved over the last decade.
@en
P2093
Carmen Martínez
Enric Carreras
Francesc Fernández-Avilés
Laura Rosiñol
Marina Díaz-Beyá
Montserrat Rovira
P304
P356
10.1016/J.BBMT.2011.06.006
P577
2011-06-25T00:00:00Z